<DOC>
	<DOCNO>NCT01608815</DOCNO>
	<brief_summary>This study design assess immunogenicity safety typhoid Vi polysaccharide vaccine Japanese participant support registration product Japan . Primary Objective : To describe seroconversion rate ( percentage subject least 4-fold increase Vi antibody titer ) Day 0 vaccination Day 28 vaccination typhoid Vi polysaccharide ( SP093 ) vaccine subject age 2 year . Secondary Objectives : - To describe safety profile single dose typhoid Vi polysaccharide vaccine 28 day vaccination , subject age 2 year . - To describe immune response follow single dose typhoid Vi polysaccharide vaccine subject age 2 year .</brief_summary>
	<brief_title>Study Single Dose SP093 Typhoid Vi Polysaccharide Vaccine Japanese Subjects</brief_title>
	<detailed_description>All participant receive single dose typhoid Vi polysaccharide vaccine Day 0 assess immunogenicity Day 0 vaccination Day 28 post-vaccination . All participant monitor safety 28 day post-vaccination .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Salmonella Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 year day inclusion For subject â‰¥ 20 year age : Informed consent form sign dated subject . For subject 2 19 year age : Informed consent form sign dated parent legally representative . Also subject 7 11 year age provide oral assent subject 12 19 year age provide write assent form Able attend schedule visits/phone call comply trial procedure For woman childbearing potential , use effective method contraception least 4 week prior vaccination least 4 week vaccination . Any acute and/or serious disease/illness , opinion investigator , stage might interfere trial conduct completion History typhoid fever Salmonella typhi infection , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity vaccine component , history life threaten reaction vaccine contain substance study vaccine Known suspect congenital current/previous acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial inclusion Planned participation another clinical trial present trial period Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine within four week precede trial vaccination , except influenza vaccination , may receive least two week study vaccine Planned receipt vaccine trial period Clinical known serological evidence systemic illness include hepatitis B , hepatitis C and/or Human immunodeficiency virus ( HIV ) infection Ineligible accord investigator 's clinical judgment Known pregnancy , positive ( serum and/or urine ) pregnancy test Currently breastfeed child Known thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator Previous vaccination Salmonella typhi disease either trial vaccine another vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Salmonella infection</keyword>
	<keyword>Typhoid fever</keyword>
	<keyword>Bacterial infection</keyword>
	<keyword>Typhoid vaccine</keyword>
</DOC>